Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Robert L. Ferris, MD, ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Federal health officials posted a warning about misleading statements by biotech billionaire Dr. Patrick Soon-Shiong about ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC.

Non-Muscle Invasive Bladder Cancer Market · GlobeNewswire Inc. The non-muscle invasive bladder cancer (NMIBC) market size has experienced robust growth, increasing from $3.66 billion in 2025 to an ...

The gall bladder is a small pouch behind the liver, deep within the abdomen, making physical detection nearly impossible ...